The earlier studies conducted by Zhang and their colleagues explicated that fisetin markedly enhanced the sensitivity of erlotinib‐resistant lung cancer cells HCC827 to erlotinib via suppressing the aberrant activation of MAPK and AKT signaling pathways resulted from AXL suppression (Klimaszewska‐Wisniewska et al., 2016; Zhang et al., 2016). The gene discussed is AXL; the disease is lung cancer.